Sign inJoin waitlistJoin the waitlist

Michael Hurwitz

Program Director, Hematology/Oncology Fellowship Program · Yale-New Haven Hospital

Credentials: · · · · ·

History

Hematology/Oncology Fellowship · Yale-New Haven Hospital
Present
Cell Therapy Clinical Research Program · Yale Cancer Center
Present
Yale-New Haven Hospital · Yale School of Medicine
Present

Dana-Farber Cancer Institute
2010–2012
Massachusetts Institute of Technology Medical Department
2007–2010
Dana-Farber Cancer Institute
2001–2004
Dana-Farber Cancer Institute
2003–2004
Internal Medicine
New York Presbyterian Hospital
1998–2000
Massachusetts Institute of Technology
Cornell Univ Joan and Sanford I Weill Med Coll
1994–1998
The Rockefeller University
1994–1997
The Rockefeller University
1997
Harvard College, Biochemical Sciences
1987–1991

Research

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2019 · 1,050 citations
Prostate Cancer, Version 1.2016
Journal of the National Comprehensive Cancer Network · 2016 · 527 citations
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Cancer Discovery · 2020 · Co-senior of 23 authors · 202 citations

Harriet Kluger
18 papers
Mario Sznol
13 papers
David Braun
8 papers
David Schoenfeld
8 papers · 8 as a fellow
AD
Adi Diab
6 papers
David McDermott
6 papers
Elizabeth Plimack
6 papers
Mehmet Bilen
6 papers
Michael Leapman
6 papers · 6 as a fellow
Adebowale Adeniran
5 papers
BC
Bryden Considine
5 papers · 3 as a fellow
Hans Hammers
5 papers

Grants

Enhancing Melanoma TIL Efficacy with Multifactor mRNA-Mediated T Cell Reprogramming
National Cancer Institute · R21
PI · $538.6K · Yale University
2023–2025
Screening of Synthetic Lethality with C. elegans Rb
National Cancer Institute · K08
Contact PI · $679.6K · Massachusetts General Hospital
2004–2009

Clinical trials

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
Principal investigator · Withdrawn · Phase 2
Yale University
2020–2023
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Principal investigator · Withdrawn · Early phase 1
Yale University
2020–2025
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Principal investigator · Completed · Phase 2
Yale University
2019–2023